| Adam B Hogue, CRNA | |
|
1710 Harrison St, Batesville, AR 72501-7303 | |
| (870) 262-1286 | |
| (870) 262-6063 |
| Full Name | Adam B Hogue |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 16 Years |
| Location | 1710 Harrison St, Batesville, Arkansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023254687 | NPI | - | NPPES |
| C02725 | Other | AR | AR LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | C02725 (Arkansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| White River Medical Center | Batesville, AR | Hospital |
| Stone County Medical Center | Mountain view, AR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| White River Health System Inc | 0143134270 | 150 |
News Archive
Pfizer Inc. has received approval from the U.S. Food and Drug Administration (FDA) for XELJANZ (tofacitinib citrate) 5 mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.
A new analysis indicates that the US opioid epidemic likely applies to the unique population of dialysis patients. The study, which appears in an upcoming issue of the Journal of the American Society of Nephrology, also found links between higher opioid drug prescription and increased risks of dialysis discontinuation, hospitalization, and early death.
Labopharm Inc. has announced that its New Drug Application (NDA) for the Company's novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder, has been accepted for review and filed by the U.S. Food and Drug Administration (FDA).
Researchers have identified a peptide and hormone that when administered to a specific area of the brain may reduce the desire for food. The study, which appears in the journal Neuropsychopharmacology, may one day lead to medications that treat obesity and binge eating disorders.
› Verified 8 days ago
| Entity Name | Jonesboro Anesthesia Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043228448 PECOS PAC ID: 6709798077 Enrollment ID: O20031104000602 |
News Archive
Pfizer Inc. has received approval from the U.S. Food and Drug Administration (FDA) for XELJANZ (tofacitinib citrate) 5 mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.
A new analysis indicates that the US opioid epidemic likely applies to the unique population of dialysis patients. The study, which appears in an upcoming issue of the Journal of the American Society of Nephrology, also found links between higher opioid drug prescription and increased risks of dialysis discontinuation, hospitalization, and early death.
Labopharm Inc. has announced that its New Drug Application (NDA) for the Company's novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder, has been accepted for review and filed by the U.S. Food and Drug Administration (FDA).
Researchers have identified a peptide and hormone that when administered to a specific area of the brain may reduce the desire for food. The study, which appears in the journal Neuropsychopharmacology, may one day lead to medications that treat obesity and binge eating disorders.
› Verified 8 days ago
| Entity Name | White River Health System Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760410229 PECOS PAC ID: 0143134270 Enrollment ID: O20031203000615 |
News Archive
Pfizer Inc. has received approval from the U.S. Food and Drug Administration (FDA) for XELJANZ (tofacitinib citrate) 5 mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.
A new analysis indicates that the US opioid epidemic likely applies to the unique population of dialysis patients. The study, which appears in an upcoming issue of the Journal of the American Society of Nephrology, also found links between higher opioid drug prescription and increased risks of dialysis discontinuation, hospitalization, and early death.
Labopharm Inc. has announced that its New Drug Application (NDA) for the Company's novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder, has been accepted for review and filed by the U.S. Food and Drug Administration (FDA).
Researchers have identified a peptide and hormone that when administered to a specific area of the brain may reduce the desire for food. The study, which appears in the journal Neuropsychopharmacology, may one day lead to medications that treat obesity and binge eating disorders.
› Verified 8 days ago
| Entity Name | Western Arkansas Anesthesiology Associates P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548202294 PECOS PAC ID: 0648179291 Enrollment ID: O20040102000767 |
News Archive
Pfizer Inc. has received approval from the U.S. Food and Drug Administration (FDA) for XELJANZ (tofacitinib citrate) 5 mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.
A new analysis indicates that the US opioid epidemic likely applies to the unique population of dialysis patients. The study, which appears in an upcoming issue of the Journal of the American Society of Nephrology, also found links between higher opioid drug prescription and increased risks of dialysis discontinuation, hospitalization, and early death.
Labopharm Inc. has announced that its New Drug Application (NDA) for the Company's novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder, has been accepted for review and filed by the U.S. Food and Drug Administration (FDA).
Researchers have identified a peptide and hormone that when administered to a specific area of the brain may reduce the desire for food. The study, which appears in the journal Neuropsychopharmacology, may one day lead to medications that treat obesity and binge eating disorders.
› Verified 8 days ago
| Entity Name | Johnson Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396794525 PECOS PAC ID: 1658360284 Enrollment ID: O20040702000283 |
News Archive
Pfizer Inc. has received approval from the U.S. Food and Drug Administration (FDA) for XELJANZ (tofacitinib citrate) 5 mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.
A new analysis indicates that the US opioid epidemic likely applies to the unique population of dialysis patients. The study, which appears in an upcoming issue of the Journal of the American Society of Nephrology, also found links between higher opioid drug prescription and increased risks of dialysis discontinuation, hospitalization, and early death.
Labopharm Inc. has announced that its New Drug Application (NDA) for the Company's novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder, has been accepted for review and filed by the U.S. Food and Drug Administration (FDA).
Researchers have identified a peptide and hormone that when administered to a specific area of the brain may reduce the desire for food. The study, which appears in the journal Neuropsychopharmacology, may one day lead to medications that treat obesity and binge eating disorders.
› Verified 8 days ago
| Entity Name | White River Health System Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427149814 PECOS PAC ID: 0143134270 Enrollment ID: O20050406001290 |
News Archive
Pfizer Inc. has received approval from the U.S. Food and Drug Administration (FDA) for XELJANZ (tofacitinib citrate) 5 mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.
A new analysis indicates that the US opioid epidemic likely applies to the unique population of dialysis patients. The study, which appears in an upcoming issue of the Journal of the American Society of Nephrology, also found links between higher opioid drug prescription and increased risks of dialysis discontinuation, hospitalization, and early death.
Labopharm Inc. has announced that its New Drug Application (NDA) for the Company's novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder, has been accepted for review and filed by the U.S. Food and Drug Administration (FDA).
Researchers have identified a peptide and hormone that when administered to a specific area of the brain may reduce the desire for food. The study, which appears in the journal Neuropsychopharmacology, may one day lead to medications that treat obesity and binge eating disorders.
› Verified 8 days ago
| Entity Name | Mena Hospital Commission |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093810392 PECOS PAC ID: 8527057678 Enrollment ID: O20070612000656 |
News Archive
Pfizer Inc. has received approval from the U.S. Food and Drug Administration (FDA) for XELJANZ (tofacitinib citrate) 5 mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.
A new analysis indicates that the US opioid epidemic likely applies to the unique population of dialysis patients. The study, which appears in an upcoming issue of the Journal of the American Society of Nephrology, also found links between higher opioid drug prescription and increased risks of dialysis discontinuation, hospitalization, and early death.
Labopharm Inc. has announced that its New Drug Application (NDA) for the Company's novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder, has been accepted for review and filed by the U.S. Food and Drug Administration (FDA).
Researchers have identified a peptide and hormone that when administered to a specific area of the brain may reduce the desire for food. The study, which appears in the journal Neuropsychopharmacology, may one day lead to medications that treat obesity and binge eating disorders.
› Verified 8 days ago
| Entity Name | White River Health System Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831495423 PECOS PAC ID: 0143134270 Enrollment ID: O20110426000404 |
News Archive
Pfizer Inc. has received approval from the U.S. Food and Drug Administration (FDA) for XELJANZ (tofacitinib citrate) 5 mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.
A new analysis indicates that the US opioid epidemic likely applies to the unique population of dialysis patients. The study, which appears in an upcoming issue of the Journal of the American Society of Nephrology, also found links between higher opioid drug prescription and increased risks of dialysis discontinuation, hospitalization, and early death.
Labopharm Inc. has announced that its New Drug Application (NDA) for the Company's novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder, has been accepted for review and filed by the U.S. Food and Drug Administration (FDA).
Researchers have identified a peptide and hormone that when administered to a specific area of the brain may reduce the desire for food. The study, which appears in the journal Neuropsychopharmacology, may one day lead to medications that treat obesity and binge eating disorders.
› Verified 8 days ago
| Entity Name | White River Health System Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477523348 PECOS PAC ID: 0143134270 Enrollment ID: O20110510000339 |
News Archive
Pfizer Inc. has received approval from the U.S. Food and Drug Administration (FDA) for XELJANZ (tofacitinib citrate) 5 mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.
A new analysis indicates that the US opioid epidemic likely applies to the unique population of dialysis patients. The study, which appears in an upcoming issue of the Journal of the American Society of Nephrology, also found links between higher opioid drug prescription and increased risks of dialysis discontinuation, hospitalization, and early death.
Labopharm Inc. has announced that its New Drug Application (NDA) for the Company's novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder, has been accepted for review and filed by the U.S. Food and Drug Administration (FDA).
Researchers have identified a peptide and hormone that when administered to a specific area of the brain may reduce the desire for food. The study, which appears in the journal Neuropsychopharmacology, may one day lead to medications that treat obesity and binge eating disorders.
› Verified 8 days ago
| Entity Name | Western Arkansas Obstetric Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952671703 PECOS PAC ID: 2365609328 Enrollment ID: O20120202000076 |
News Archive
Pfizer Inc. has received approval from the U.S. Food and Drug Administration (FDA) for XELJANZ (tofacitinib citrate) 5 mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.
A new analysis indicates that the US opioid epidemic likely applies to the unique population of dialysis patients. The study, which appears in an upcoming issue of the Journal of the American Society of Nephrology, also found links between higher opioid drug prescription and increased risks of dialysis discontinuation, hospitalization, and early death.
Labopharm Inc. has announced that its New Drug Application (NDA) for the Company's novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder, has been accepted for review and filed by the U.S. Food and Drug Administration (FDA).
Researchers have identified a peptide and hormone that when administered to a specific area of the brain may reduce the desire for food. The study, which appears in the journal Neuropsychopharmacology, may one day lead to medications that treat obesity and binge eating disorders.
› Verified 8 days ago
| Entity Name | Youngs Professional Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922178599 PECOS PAC ID: 2163524992 Enrollment ID: O20200218000624 |
News Archive
Pfizer Inc. has received approval from the U.S. Food and Drug Administration (FDA) for XELJANZ (tofacitinib citrate) 5 mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.
A new analysis indicates that the US opioid epidemic likely applies to the unique population of dialysis patients. The study, which appears in an upcoming issue of the Journal of the American Society of Nephrology, also found links between higher opioid drug prescription and increased risks of dialysis discontinuation, hospitalization, and early death.
Labopharm Inc. has announced that its New Drug Application (NDA) for the Company's novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder, has been accepted for review and filed by the U.S. Food and Drug Administration (FDA).
Researchers have identified a peptide and hormone that when administered to a specific area of the brain may reduce the desire for food. The study, which appears in the journal Neuropsychopharmacology, may one day lead to medications that treat obesity and binge eating disorders.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Adam B Hogue, CRNA Po Box 2197, Batesville, AR 72503-2197 Ph: (870) 262-3280 | Adam B Hogue, CRNA 1710 Harrison St, Batesville, AR 72501-7303 Ph: (870) 262-1286 |
News Archive
Pfizer Inc. has received approval from the U.S. Food and Drug Administration (FDA) for XELJANZ (tofacitinib citrate) 5 mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.
A new analysis indicates that the US opioid epidemic likely applies to the unique population of dialysis patients. The study, which appears in an upcoming issue of the Journal of the American Society of Nephrology, also found links between higher opioid drug prescription and increased risks of dialysis discontinuation, hospitalization, and early death.
Labopharm Inc. has announced that its New Drug Application (NDA) for the Company's novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder, has been accepted for review and filed by the U.S. Food and Drug Administration (FDA).
Researchers have identified a peptide and hormone that when administered to a specific area of the brain may reduce the desire for food. The study, which appears in the journal Neuropsychopharmacology, may one day lead to medications that treat obesity and binge eating disorders.
› Verified 8 days ago
Mr. Richard Alan Alberti, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1710 Harrison St, Batesville, AR 72501 Phone: 870-262-1200 Fax: 870-262-6063 | |
Mr. Steven Clay Chaffin, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1710 Harrison St, Batesville, AR 72501 Phone: 870-262-1200 Fax: 870-262-6063 | |
Mrs. Karen Diane Walls, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1710 Harrison St, Batesville, AR 72501 Phone: 870-262-1200 Fax: 870-262-6063 | |
Mr. David Ross Cox, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1710 Harrison St, Batesville, AR 72501 Phone: 870-262-1200 Fax: 870-262-6063 | |
Charles O Vaugier, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1710 Harrison St, Batesville, AR 72501 Phone: 870-262-1200 | |
Zelda R. Epperson-may, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1710 Harrison St, Batesville, AR 72501 Phone: 870-262-1235 Fax: 870-262-3170 |